Bristol-Myers Squibb Earnings & Forecasts

Bristol-Myers Squibb (BMY) earnings history, EPS estimates, revenue forecasts and company guidance.

Earnings Per Share (Non-GAAP)

분기별 실적 서프라이즈 금액

회계 분기	보고된 날짜	실제 EPS	예상 EPS	놀라다 %
Q2	Jul 30, 2026	$2.04	$1.61	26.7 %
Q1	Apr 30, 2026	$1.58	$1.43	10.5 %
Q4	Feb 5, 2026	$1.26	$1.19	5.88 %
Q3	Oct 30, 2025	$1.63	$1.51	7.95 %

Quarterly Revenue (Billions)

분기별 수익 깜짝 금액

회계 분기	보고된 날짜	실제 수익	예상 수익	놀라다 %
Q2	Jul 30, 2026	$12.97B	$11.70B	10.9 %
Q1	Apr 30, 2026	$11.49B	$10.92B	5.23 %
Q4	Feb 5, 2026	$12.50B	$12.27B	1.93 %
Q3	Oct 30, 2025	$12.22B	$11.81B	3.47 %

Bristol-Myers Squibb Guidance

Bristol-Myers Squibb (BMY)은 지난 7월 30, 2026에 fiscal year 2026의 실적 전망을 발표했습니다. 회사는 주당순이익을 $6.75 - $7 범위로 전망했으며, 이는 시장 컨센서스 EPS 추정치인 $6.31보다 높은 수치입니다. Bristol-Myers Squibb는 또한 해당 기간의 매출을 $49B - $50B 범위로 전망했습니다.

이전 가이던스와 비교하여 Bristol-Myers Squibb는 주당순이익(EPS) 전망치를 이전 범위인 상향 조정됨에서 $6.05 - $6.35로 상향 조정했습니다. 매출 측면에서는 회사가 매출 전망치를 이전 범위인 상향 조정됨에서 $46B - $47.5B로 상향 조정했습니다.

Bristol-Myers Squibb은 16과 10월 25, 2022 사이에 7월 30, 2026개의 지침 업데이트를 발표했습니다. During this period, the company raised its outlook 6 times and lowered it 6 times, providing investors with insight into management's evolving expectations.

Recent Earnings Results

Metric	Q2 '26	Q1 '26	Q4 '25	Q3 '25
Earnings Per Share (Non-GAAP)
Estimate	$1.61	$1.43	$1.19	$1.51
Actual	$2.04	$1.58	$1.26	$1.63
Surprise	+26.7%	+10.5%	+5.88%	+7.95%
Revenue
Estimate	$11.70B	$10.92B	$12.27B	$11.81B
Actual	$12.97B	$11.49B	$12.50B	$12.22B
Surprise	+10.9%	+5.23%	+1.93%	+3.47%

Analyst Estimates — Forward PeriodsSource: Wall Street consensus

Metric	Q3 '26E	Q4 '26E	Q1 '27E	Q2 '27E
Earnings Per Share (Non-GAAP)
Consensus	$1.72	$1.61	$1.44	$1.71
Revenue
Consensus	$12.64B	$12.71B	—	—

More with Benzinga EdgeGet Access

Earnings & Guidance News

Oil Sinks 6%, Nasdaq 100 Rallies On Iran Talks: Stock Market Today

Crude tumbles nearly 6% after Trump cancels a strike on Iran, lifting the S&P 500 1.3% and the Russell 2000 1.5% at midday Monday.

Piero Cingari

Bristol-Myers Boosts 2026 Guidance on Portfolio Strength

Bristol-Myers beats Q2 earnings and revenue estimates, driven by growth drugs, while raising its full-year 2026 sales and profit outlook.

Vandana Singh

PRO
Bristol-Myers Squibb Raises FY2026 Adj EPS Guidance from $6.05-$6.35 to $6.75-$7.00 vs $6.34 Est; Raises FY2026 Sales Guidance from $46.000B-$47.500B to $49.000B-$50.000B vs $47.472B Est

Bristol-Myers Squibb (NYSE:BMY) raises FY2026 Adj EPS guidance from $6.05-$6.35 to $6.75-$7.00 vs $6.34 analyst estimate. Raises FY2026 sales outlook from $46.000 billion-$47.500 billion to $49.000 billion-$50.000

Benzinga Newsdesk

Bristol-Myers Squibb Co